PMID- 28256194
OWN - NLM
STAT- MEDLINE
DCOM- 20180702
LR  - 20220318
IS  - 1555-3906 (Electronic)
IS  - 0965-0407 (Print)
IS  - 0965-0407 (Linking)
VI  - 25
IP  - 8
DP  - 2017 Sep 21
TI  - Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in 
      Breast Cancer Patients.
PG  - 1223-1229
LID - 10.3727/096504017X14876245096439 [doi]
AB  - Doxorubicin (DOX) is a commonly used antineoplastic agent for the treatment of 
      various malignancies, and its use is associated with unpredictable 
      cardiotoxicity. Susceptibility to DOX cardiotoxicity is largely patient 
      dependent, suggesting genetic predisposition. We have previously found that 
      individual sensitivity to DOX cardiotoxicity was associated with differential 
      expression of genes implicated in inflammatory response and immune trafficking, 
      which was consistent with the increasing number of reports highlighting the 
      important role of human leukocyte antigen (HLA) complex polymorphism in 
      hypersensitivity to drug toxicity. This pilot study aimed to investigate DNA from 
      patients treated with DOX-based chemotherapy for breast cancer and to correlate 
      the results with the risk for DOX-associated cardiotoxicity. We have identified 
      18 SNPs in nine genes in the HLA region (NFKBIL1, TNF-alpha, ATP6V1G2-DDX39B, MSH5, 
      MICA, LTA, BAT1, and NOTCH4) and in the psoriasis susceptibility region of HLA-C 
      as potential candidates for association with DOX cardiotoxicity. These results, 
      albeit preliminary and involving a small number of patients, are consistent with 
      reports showing the presence of susceptibility loci within the HLA gene region 
      for several inflammatory and autoimmune diseases, and with our previous findings 
      indicating that the increased sensitivity to DOX cardiotoxicity was associated 
      with dysregulation of genes implicated both in inflammation and autoimmune 
      disorders.
FAU - Todorova, Valentina K
AU  - Todorova VK
FAU - Makhoul, Issam
AU  - Makhoul I
FAU - Dhakal, Ishwori
AU  - Dhakal I
FAU - Wei, Jeanne
AU  - Wei J
FAU - Stone, Annjanette
AU  - Stone A
FAU - Carter, Weleetka
AU  - Carter W
FAU - Owen, Aaron
AU  - Owen A
FAU - Klimberg, V Suzanne
AU  - Klimberg VS
LA  - eng
GR  - P30 AG028718/AG/NIA NIH HHS/United States
GR  - UL1 RR029884/RR/NCRR NIH HHS/United States
PT  - Journal Article
DEP - 20170302
PL  - United States
TA  - Oncol Res
JT  - Oncology research
JID - 9208097
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibiotics, Antineoplastic/*adverse effects
MH  - Breast Neoplasms/*complications/pathology
MH  - Cardiotoxicity/*etiology
MH  - Doxorubicin/*adverse effects
MH  - Female
MH  - Humans
MH  - Middle Aged
MH  - Polymorphism, Genetic
PMC - PMC7841056
EDAT- 2017/03/04 06:00
MHDA- 2018/07/03 06:00
PMCR- 2017/09/21
CRDT- 2017/03/04 06:00
PHST- 2017/03/04 06:00 [pubmed]
PHST- 2018/07/03 06:00 [medline]
PHST- 2017/03/04 06:00 [entrez]
PHST- 2017/09/21 00:00 [pmc-release]
AID - OR1051 [pii]
AID - 10.3727/096504017X14876245096439 [doi]
PST - ppublish
SO  - Oncol Res. 2017 Sep 21;25(8):1223-1229. doi: 10.3727/096504017X14876245096439. 
      Epub 2017 Mar 2.